Drug Repurposing and Lysosomal Storage Disorders : A Trick to Treat
Rare diseases, or orphan diseases, are defined as diseases affecting a small number of people compared to the general population. Among these, we find lysosomal storage disorders (LSDs), a cluster of rare metabolic diseases characterized by enzyme mutations causing abnormal glycolipid storage. Drug repositioning involves repurposing existing approved drugs for new therapeutic applications, offering advantages in cost, time savings, and a lower risk of failure. We present a comprehensive analysis of existing drugs, their repurposing potential, and their clinical implications in the context of LSDs, highlighting the necessity of mutation-specific approaches. Our review systematically explores the landscape of drug repositioning as a means to enhance LSDs therapies. The findings advocate for the strategic repositioning of drugs, accentuating its role in expediting the discovery of effective treatments. We conclude that drug repurposing represents a viable pathway for accelerating therapeutic discovery for LSDs, emphasizing the need for the careful evaluation of drug efficacy and toxicity in disease-specific contexts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Genes - 15(2024), 3 vom: 25. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hay Mele, Bruno [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug repositioning |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 30.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/genes15030290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370298950 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370298950 | ||
| 003 | DE-627 | ||
| 005 | 20240331001547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/genes15030290 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM370298950 | ||
| 035 | |a (NLM)38540351 | ||
| 035 | |a (PII)290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hay Mele, Bruno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repurposing and Lysosomal Storage Disorders |b A Trick to Treat |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Rare diseases, or orphan diseases, are defined as diseases affecting a small number of people compared to the general population. Among these, we find lysosomal storage disorders (LSDs), a cluster of rare metabolic diseases characterized by enzyme mutations causing abnormal glycolipid storage. Drug repositioning involves repurposing existing approved drugs for new therapeutic applications, offering advantages in cost, time savings, and a lower risk of failure. We present a comprehensive analysis of existing drugs, their repurposing potential, and their clinical implications in the context of LSDs, highlighting the necessity of mutation-specific approaches. Our review systematically explores the landscape of drug repositioning as a means to enhance LSDs therapies. The findings advocate for the strategic repositioning of drugs, accentuating its role in expediting the discovery of effective treatments. We conclude that drug repurposing represents a viable pathway for accelerating therapeutic discovery for LSDs, emphasizing the need for the careful evaluation of drug efficacy and toxicity in disease-specific contexts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a lysosomal enzyme disorder | |
| 650 | 4 | |a lysosomal storage disease | |
| 650 | 4 | |a lysosomal storage disorder | |
| 700 | 1 | |a Rossetti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Cubellis, Maria Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Monticelli, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Andreotti, Giuseppina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genes |d 2010 |g 15(2024), 3 vom: 25. Feb. |w (DE-627)NLM220446326 |x 2073-4425 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:3 |g day:25 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/genes15030290 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 3 |b 25 |c 02 | ||